GRAIL

Market position

GRAIL describes itself as pioneering the multi-cancer early detection category and positions Galleri as a first-of-its-kind MCED test; Wikipedia notes it was the first such test the company launched commercially in June 2021. Financial data providers classify GRAIL in the Diagnostics & Research industry alongside peers including Illumina, Guardant Health, Natera, Exact Sciences, GeneDx, Personalis and BillionToOne. With a market capitalization of roughly $3.3-3.6 billion in August 2026, it is substantially smaller than several of those comparables.

GRAIL differentiates on a single blood draw that screens for signals from more than 50 cancer types — including many without recommended screening tests — rather than one cancer at a time, supported by a targeted methylation platform and what the company describes as the largest database of cancer and non-cancer methylation signatures. Company materials cite a false positive rate of less than one percent in clinical data and the ability to predict tissue of origin when a signal is detected. Its evidence base spans population-scale studies with more than 380,000 participants, and it holds FDA Breakthrough Device Designation for its MCED test.

Technology

GRAIL's platform uses next-generation sequencing of cell-free DNA combined with targeted methylation analysis, machine-learning algorithms, software and automation. The methylation-based approach preferentially targets informative regions of the genome, and the company states it uses a proprietary sequencing database of cancer and non-cancer methylation signatures — which it believes is the largest of its kind — both to detect the presence of cancer and to predict the tumor's tissue of origin. CCGA discovery results published in Cancer Cell in November 2022 identified methylation as a promising DNA hallmark for multi-cancer detection. Testing is performed in CAP-accredited, CLIA-certified laboratories exceeding 170,000 square feet.

Go-to-market

Galleri is available in the United States by prescription and is distributed through partnerships that broaden access: health systems (Providence was announced in March 2021 as the first health system to offer Galleri), employers and public-sector institutions (including a collaboration with the U.S. Department of Veterans Affairs and the Veterans Health Foundation announced in May 2022 and a fire department program featured in patient stories), life insurance carriers (John Hancock became the first life insurance carrier to offer access in September 2022), and national health systems (the NHS England partnership and trial). The company also pursues pharmaceutical collaborations, such as a strategic collaboration with AstraZeneca announced in June 2022 to develop companion diagnostics for early-stage cancer treatment. GRAIL is pursuing FDA premarket approval for Galleri, with an FDA advisory committee meeting announced for review of the PMA application.

Asymptomatic adults, generally over the age of 50, who are eligible for cancer screening; patients with clinical suspicion of cancer (for the diagnostic aid product); and institutional buyers and partners including healthcare systems, employers, government agencies such as the U.S. Department of Veterans Affairs, life insurance carriers, national health services such as NHS England, and pharmaceutical companies purchasing development services.

Geography

Headquartered in Menlo Park, California, with operations described as serving the United States and internationally. Historical company materials cite a Washington, D.C. presence, a clinical site in Research Triangle Park, North Carolina, and expansion to the United Kingdom, where GRAIL partnered with the NHS; a president for Europe role has been held by Harpal Kumar. Laboratory facilities total more than 170,000 square feet.

History

GRAIL was founded in 2015 (company history materials cite January 2016 as the founding month of the spun-out entity) as an Illumina subsidiary. It announced the Circulating Cell-free Genome Atlas (CCGA) study in December 2016, raised an initial $100 million Series A followed by a $1 billion Series B announced in March 2017, and acquired Cirina along with key methylation intellectual property that same month. The STRIVE study began in April 2017, AACR data supporting multi-cancer detection was presented in July 2018, and the SUMMIT study was announced in December 2018. In May 2019 GRAIL received FDA Breakthrough Device Designation for its MCED test and announced $300 million in Series C funding, followed by a $390 million Series D in May 2020. The PATHFINDER study began enrolling in February 2020, validation data covering 50+ cancers was published in Annals of Oncology in March 2020, and a partnership with the UK's National Health Service was announced in November 2020. Galleri launched commercially by prescription in the United States in June 2021, the same year Providence became the first health system to offer it and the NHS launched its UK trial. Illumina announced an agreement to acquire GRAIL outright for $7.1 billion in September 2020, completing the purchase in 2021; the FTC sued to block the vertical merger in March 2021 and an administrative judge ruled against the FTC's position in September 2022. In October 2023 the European Commission ordered divestment, the EC approved Illumina's divestment plan in April 2024, and the spin-off was completed on June 24, 2024, with GRAIL listing on Nasdaq as GRAL and Illumina retaining a 14.5% stake.

Risks & controversies

Wikipedia records several criticisms and legal matters: early trial results were described as poor despite promotion of the test as a potentially life-saving advance; a large-scale NHS England trial was characterized by critics as overhyped and unethical; a 2024 BMJ investigation questioned the evidence for the test; and as of 2024 GRAIL was facing discontent and legal action from investors. In June 2023 the company disclosed that letters were mailed to 408 patients incorrectly informing them they may have cancer, which GRAIL attributed to a software configuration issue at PWNHealth rather than incorrect Galleri results. The Illumina acquisition drew an FTC suit in March 2021 and a European Commission divestment order in October 2023. Eric Topol reported a sensitivity of only 40% for PATHFINDER 2, with false negatives failing to detect cancers that emerged during 12-month follow-up, and those results remained unpublished as of October 2025. The company is deeply lossmaking (2024 operating loss of about $2.2 billion; TTM net loss of about $391.6 million) and its regulatory path depends on the pending FDA premarket approval decision.